I
Inovio Pharmaceuticals, Inc. (INO)
NCM – Real Time Price. Currency in USD
0.84
+0.04 (5.48%)
At close: Oct 22, 2026, 4:00 PM EDT
0.85
+0.01 (1.32%)
After-hours: Oct 22, 2026, 7:40 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.84
+0.04 (5.48%)
At close: Oct 22, 2026, 4:00 PM EDT
0.85
+0.01 (1.32%)
After-hours: Oct 22, 2026, 7:40 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $31.5M significantly exceed its total debt $8.0M, ensuring strong financial flexibility
Total current assets $39.9M are just enough to cover Total current liabilities $39.9M, indicating tight liquidity
Debt-to-equity ratio (1.8) far exceeds the industry average, reflecting over-leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$18.0M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.00 | 4.66 | 6.0 | |
| Quick ratio | 1.00 | 4.27 | 6.0 | |
| Debt to Equity | 1.83 | 0.15 | 3.0 | |
| Debt to Assets | 0.16 | 0.11 | 8.0 | |
| Interest coverage | N/A | -3.18 | 1.0 | |
| Weighted average score | 4.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 10M | 832K | 218K | 65K | N/A |
| Gross Profit | 5M | -3M | -3M | -3M | -3M |
| Operating Income | -274M | -135M | -114M | -87M | -79M |
| Net Income | -280M | -135M | -107M | -85M | -67M |
| EBITDA | -269M | -132M | -111M | -84M | -76M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | 83.18 | 1.0 | |
| Operating margin % | N/A | -29.82 | 1.0 | |
| Net margin % | N/A | -41.34 | 1.0 | |
| EBITDA margin % | N/A | -26.03 | 1.0 | |
| Cash flow margin % | N/A | -43.91 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| ROA | -112.56 | -20.69 | 1.0 | |
| ROE | -304.53 | -17.54 | 1.0 | |
| ROIC | -236.59 | -18.98 | 1.0 | |
| ROCE | -599.27 | -25.49 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 77.39 | 5.5 |
| Next quarter | N/A | -405.56 | 1.0 |
| Current year | 920.26 | 57.83 | 10 |
| Next year | 7490 | 44.1 | 10 |
| Weighted average score | 6.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 69.45 | 75 | 16.41 | 9.8 |
| Y/Y | 999 | 74.44 | 88.52 | 13.41 | 9.5 |
| 3y average | -78.55 | 31.04 | 48.65 | 24.57 | 7.8 |
| 5y average | 33.3 | 3.7 | 25.95 | 10.55 | 7.8 |
| Weighted average score | 8.7 | ||||
| NAME | RATIO | INDUSTRY | 5Q TREND | SCORE |
|---|---|---|---|---|
| P/E | N/A | 20.20 | 1.0 | |
| PEG (5yr expected) | N/A | 1.20 | 1.0 | |
| P/S | N/A | 10.07 | 1.0 | |
| P/B | 14.98 | 4.38 | 2.8 | |
| Weighted average score | 1.5 | |||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | N/A | 1.20 | N/A |
| Payout ratio | N/A | 27.45 | N/A |
| 5-year dividend growth rate | N/A | 4.94 | N/A |
| Years of dividend increase | 0.00 | 0.00 | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | N/A | N/A |
| Intangible assets | N/A | N/A |
| Switching costs | N/A | N/A |
| Network effect | N/A | N/A |
| Economies of scale | N/A | N/A |
| Weighted average score | 1.0 | |